<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15126">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02117908</url>
  </required_header>
  <id_info>
    <org_study_id>CPAP-RFP</org_study_id>
    <nct_id>NCT02117908</nct_id>
  </id_info>
  <brief_title>Study of the Application of CPAP to Reduce Complications and Improve Lung Cancer Ablation Radiofrequency Treatment</brief_title>
  <acronym>CPAP-RFP</acronym>
  <official_title>Application of CPAP to Reduce Complications and Improve Treatment of Radiofrequency Ablation of Lung Cancer Under Conscious Sedation. A Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sara Varea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spanish Ministry of Economy and competitivity</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion Clinic per a la Recerca Biomédica</source>
  <oversight_info>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project aims to study whether the application of a continuous positive airway pressure
      (CPAP) of 4 cm water vapor is a safe method  in pulmonary radiofrequency intervention (PRF)
      lung cancer under conscious sedation compared with placebo. And, assess whether CPAP
      prevents atelectasis formation and consequently reduces the potential complications of PRF
      and improves procedural success
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety</measure>
    <time_frame>thirty days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients with any of the following complications
Pulmonary over-distention along intervention Pneumothorax along intervention Bronchial fistulas measures Computed tomography (CT)1, CT2 and CT3 Vomiting along intervention Decrease in MAP (mean arterial pressure) &gt; 20% measured in the intraoperative period
Assay of each of the previous complications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevention of atelectasis.</measure>
    <time_frame>during surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Atelectasic area Normal ventilation pulmonary area Hypoventilation pulmonary area Hyperventilation  pulmonary area Bronchial wall injury distance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease associated complications with PFR. Measurement times: intraoperative, PACU (post-anesthesic care unit), hospital discharge, day 15 and day 30.</measure>
    <time_frame>thirty days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Major complications (death, failure to complete treatment, need for manual ventilation, intubation or resuscitation, pulmonary hemorrhage, need for pleural drainage, shock, fistulas, nerve injury, diaphragmatic injury, persistent pain, infections, increased hospitalization time and readmission rates) and any classified as a serious adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment success</measure>
    <time_frame>Measurement time: CT3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tumor ablation range, measured in CT3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictors factors of the occurrence of complications during PRA (pulmonary radiofrequency ablation).</measure>
    <time_frame>thirty days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Minor complications (transient episodes of hypoxemia, apnea / hypoventilation or hypotension, pneumothorax without clinic symptoms or drainage, increased need for sedation, longer procedure) and any other event  adverse not classified as serious.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Atelectasis</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>CPAP +4 cm H2O</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPAP +4 cm H2O pressure using ResMedTM face mask</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ShamCPAP</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>shamCPAP using ResMedTM CPAP face mask modified for technical sham</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RESMED AUTOSET S9</intervention_name>
    <description>Continuous positive pressure during surgery</description>
    <arm_group_label>CPAP +4 cm H2O</arm_group_label>
    <arm_group_label>ShamCPAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male and female aged 18 years and older

          -  Patient with a scheduled intervention  for ablation of pulmonary malignant tumor with
             radiofrequency .

          -  Patient able to undergo tests and examinations required by the study.

        Exclusion Criteria:

          -  Patients with CPAP intolerance test.

          -  Patients with progressive disease in which local treatment is not applicable

          -  Patients with intercurrent process (pleural effusion, pneumonia, ...).

          -  Patient unable to understand the proceedings.

          -  Pregnancy or breastfeeding.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique J Carrero Cardenal, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínic i Provincial de Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Enrique J Carrero, MD, PhD</last_name>
    <phone>+34932275400</phone>
    <email>ecarrero@clinic.ub.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clinic of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sara Varea, BS (Biology)</last_name>
      <phone>+34932275400</phone>
      <phone_ext>3343</phone_ext>
      <email>svarea@clinic.ub.es</email>
    </contact>
    <contact_backup>
      <last_name>Joan A Arnaiz, MD, PhD</last_name>
      <phone>+34932275400</phone>
      <phone_ext>9838</phone_ext>
      <email>jaarnaiz@clinic.ub.es</email>
    </contact_backup>
    <investigator>
      <last_name>Enrique J Carrero Cardenal, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 22, 2014</lastchanged_date>
  <firstreceived_date>April 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundació Clínic per la Recerca Biomèdica</investigator_affiliation>
    <investigator_full_name>Sara Varea</investigator_full_name>
    <investigator_title>Clinical Research Manager</investigator_title>
  </responsible_party>
  <keyword>prevention</keyword>
  <keyword>radiofrequency treatment</keyword>
  <keyword>lung cancer ablation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pulmonary Atelectasis</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
